title: High-dose chemotherapy followed by autologous and allogeneic hematopoietic stem cell transplantation in patients with follicular non-Hodgkin’s lymphoma in the rituximab era.
abstract: High-dose chemotherapy in lymphomas, and mainly non-Hodgkin’s lymphomas, has been advancing since the 1970s. This therapeutic strategy is based on the supposed existence of a dose-response curve for cytotoxic agents. However, the available data are contradictory, so high-dose chemotherapy cannot be guaranteed as consolidation treatment for first-remission follicular lymphoma or diffuse large cell lymphoma. The objective of this paper is to review the current knowledge about high-dose chemotherapy followed by hematopoietic stem cell transplantation in follicular non-Hodgkin’s lymphoma. The published studies on follicular lymphoma after first remission, recurrent follicular lymphoma, and transformed follicular ­lymphoma were assessed together with the data available on diffuse large cell lymphoma. During analysis of the studies, difficulties were encountered in comparing studies due to the heterogeneous nature of the data. High-dose chemotherapy as consolidation treatment after first remission or in recurrent or refractory disease was also analyzed.
authors.forename: Ignacio García
authors.initials: IG
authors.lastname: Escobar
authors.forename: Blanca Cantos
authors.initials: BC
authors.lastname: Sánchez de Ibarguen
authors.forename: Virginia Calvo
authors.initials: VC
authors.lastname: de Juan
authors.forename: C Maximiano
authors.initials: CM
authors.lastname: Alonso
authors.forename: Miriam Méndez
authors.initials: MM
authors.lastname: García
authors.forename: Antonio Carlos Sánchez
authors.initials: AC
authors.lastname: Ruíz
authors.forename: Mariano Provencio
authors.initials: MP
authors.lastname: Pulla
mesh_terms: D058846:Antibodies, Monoclonal, Murine-Derived / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D016465:Bone Marrow Purging; D002986:Clinical Trials as Topic; D004334:Drug Administration Schedule; D019317:Evidence-Based Medicine; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use*; D008224:Lymphoma, Follicular / Q000188:drug therapy / Q000601:surgery / Q000628:therapy*; D020360:Neoadjuvant Therapy / Q000379:methods*; D012008:Recurrence; D000069283:Rituximab; D014182:Transplantation, Autologous; D014184:Transplantation, Homologous; D016896:Treatment Outcome
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D007155:Immunologic Factors; D000069283:Rituximab